Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML

Following the success of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapies against B-cell malignancies, the CAR T-cell approach is being developed towards other malignancies like acute myeloid leukemia (AML). Treatment options for relapsed AML patients are limited, and the upregulation...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Maya Graham, Møller, Bjarne Kuno, Bak, Rasmus O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598885/
https://www.ncbi.nlm.nih.gov/pubmed/36289703
http://dx.doi.org/10.3390/biomedicines10102441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598885/
https://www.ncbi.nlm.nih.gov/pubmed/36289703
http://dx.doi.org/10.3390/biomedicines10102441

Ejemplares similares